+

WO2008070268A3 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
WO2008070268A3
WO2008070268A3 PCT/US2007/080831 US2007080831W WO2008070268A3 WO 2008070268 A3 WO2008070268 A3 WO 2008070268A3 US 2007080831 W US2007080831 W US 2007080831W WO 2008070268 A3 WO2008070268 A3 WO 2008070268A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
analgesic
treat
eliminate
subject
Prior art date
Application number
PCT/US2007/080831
Other languages
English (en)
Other versions
WO2008070268A2 (fr
Inventor
Paul Bosse
Original Assignee
Charleston Lab Inc
Paul Bosse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2665841A priority Critical patent/CA2665841C/fr
Priority to JP2009531645A priority patent/JP2010522135A/ja
Priority to EP07871139.7A priority patent/EP2124556B1/fr
Priority to US12/444,521 priority patent/US8653066B2/en
Priority to SI200731562T priority patent/SI2124556T1/sl
Priority to PL07871139T priority patent/PL2124556T3/pl
Priority to DK07871139.7T priority patent/DK2124556T3/en
Priority to ES07871139.7T priority patent/ES2524556T3/es
Application filed by Charleston Lab Inc, Paul Bosse filed Critical Charleston Lab Inc
Publication of WO2008070268A2 publication Critical patent/WO2008070268A2/fr
Publication of WO2008070268A3 publication Critical patent/WO2008070268A3/fr
Priority to HK10105451.9A priority patent/HK1138732A1/xx
Priority to US14/099,432 priority patent/US20140134248A1/en
Priority to US14/748,605 priority patent/US9402813B2/en
Priority to US14/748,614 priority patent/US9393207B2/en
Priority to US14/748,621 priority patent/US9427407B2/en
Priority to US14/748,613 priority patent/US20150328210A1/en
Priority to US14/748,609 priority patent/US9399022B2/en
Priority to US14/748,617 priority patent/US20150328212A1/en
Priority to US15/263,235 priority patent/US20160375014A1/en
Priority to US15/263,230 priority patent/US20160375013A1/en
Priority to US15/679,460 priority patent/US20170340627A1/en
Priority to US16/425,401 priority patent/US20200054625A1/en
Priority to US17/229,479 priority patent/US20220062276A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques qui comportent des quantités efficaces d'analgésique pour traiter un sujet, y compris pour réduire ou éliminer un effet indésirable associé à l'analgésique.
PCT/US2007/080831 2006-10-09 2007-10-09 Compositions pharmaceutiques WO2008070268A2 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
JP2009531645A JP2010522135A (ja) 2006-10-09 2007-10-09 医薬組成物
EP07871139.7A EP2124556B1 (fr) 2006-10-09 2007-10-09 Compositions pharmaceutiques
US12/444,521 US8653066B2 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
SI200731562T SI2124556T1 (sl) 2006-10-09 2007-10-09 Farmacevtske sestave
PL07871139T PL2124556T3 (pl) 2006-10-09 2007-10-09 Kompozycje farmaceutyczne
CA2665841A CA2665841C (fr) 2006-10-09 2007-10-09 Compositions pharmaceutiques
DK07871139.7T DK2124556T3 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
ES07871139.7T ES2524556T3 (es) 2006-10-09 2007-10-09 Composiciones farmacéuticas
HK10105451.9A HK1138732A1 (en) 2006-10-09 2010-06-02 Pharmaceutical compositions
US14/099,432 US20140134248A1 (en) 2006-10-09 2013-12-06 Pharmaceutical compositions
US14/748,617 US20150328212A1 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,605 US9402813B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,609 US9399022B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,614 US9393207B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,621 US9427407B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,613 US20150328210A1 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US15/263,235 US20160375014A1 (en) 2006-10-09 2016-09-12 Pharmaceutical compositions
US15/263,230 US20160375013A1 (en) 2006-10-09 2016-09-12 Pharmaceutical compositions
US15/679,460 US20170340627A1 (en) 2006-10-09 2017-08-17 Pharmaceutical compositions
US16/425,401 US20200054625A1 (en) 2006-10-09 2019-05-29 Pharmaceutical Compositions
US17/229,479 US20220062276A1 (en) 2006-10-09 2021-04-13 Pharmaceutical compositions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85045106P 2006-10-09 2006-10-09
US60/850,451 2006-10-09
US95256307P 2007-04-03 2007-04-03
US60/952,563 2007-04-03
US94837507P 2007-07-06 2007-07-06
US60/948,375 2007-07-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/444,521 A-371-Of-International US8653066B2 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
US14/099,432 Continuation US20140134248A1 (en) 2006-10-09 2013-12-06 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO2008070268A2 WO2008070268A2 (fr) 2008-06-12
WO2008070268A3 true WO2008070268A3 (fr) 2008-11-27

Family

ID=39492908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080831 WO2008070268A2 (fr) 2006-10-09 2007-10-09 Compositions pharmaceutiques

Country Status (3)

Country Link
CA (1) CA2918576C (fr)
PT (1) PT2124556E (fr)
WO (1) WO2008070268A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
US9198867B2 (en) 2008-01-09 2015-12-01 Charleston Laboratories, Inc. Pharmaceutical compositions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2184276A1 (fr) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Procédé de préparation de nouvelles 1H-benzo(d) imidazol-2(3h)-ones substituées, de nouveaux intermédiaires et leur utilisation en tant qu'inhibiteurs de bace 1
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
WO2011063164A2 (fr) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Médicaments de cannabinoïde à libération prolongée
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
GB2541571A (en) * 2014-04-10 2017-02-22 Charleston Laboratories Inc Pharmaceutical compositions
WO2015157509A1 (fr) * 2014-04-10 2015-10-15 The Trustees Of The University Of Pennsylvania Compositions et methodes de traitement de maladies associées aux recepteurs des opioides
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
WO2017066488A1 (fr) * 2015-10-13 2017-04-20 Charleston Laboratories, Inc. Traitement de la douleur à l'aide d'une composition comprenant un opioïde et un antiémétique
WO2017152130A1 (fr) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Compositions pharmaceutiques
CA3066113A1 (fr) * 2016-06-10 2017-12-14 Charleston Laboratories, Inc. Compositions pharmaceutiques comprenant un analgesique opioide et un antiemetique pour traiter la douleur
EP4181912A1 (fr) 2020-07-15 2023-05-24 Schabar Research Associates LLC Compositions de dose orale unitaire composées d'ibuprofène et de famotidine pour le traitement de la douleur aiguë et la réduction de la gravité et/ou du risque de brûlures d'estomac
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
US5738874A (en) * 1992-09-24 1998-04-14 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
US5738874A (en) * 1992-09-24 1998-04-14 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2124556A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US9393207B2 (en) 2006-10-09 2016-07-19 Locl Pharma, Inc. Pharmaceutical compositions
US9399022B2 (en) 2006-10-09 2016-07-26 Locl Pharma, Inc. Pharmaceutical compositions
US9402813B2 (en) 2006-10-09 2016-08-02 Locl Pharma, Inc. Pharmaceutical compositions
US9427407B2 (en) 2006-10-09 2016-08-30 Locl Pharma, Inc. Pharmaceutical compositions
US9198867B2 (en) 2008-01-09 2015-12-01 Charleston Laboratories, Inc. Pharmaceutical compositions
US9226901B2 (en) 2008-01-09 2016-01-05 Locl Pharma, Inc. Pharmaceutical compositions
US9387177B2 (en) 2008-01-09 2016-07-12 Locl Pharma, Inc. Pharmaceutical compositions
US9498444B2 (en) 2008-01-09 2016-11-22 Locl Pharma, Inc. Pharmaceutical compositions
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
US9433625B2 (en) 2009-07-08 2016-09-06 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain
US9526704B2 (en) 2009-07-08 2016-12-27 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain

Also Published As

Publication number Publication date
CA2918576C (fr) 2019-01-08
PT2124556E (pt) 2014-12-03
CA2918576A1 (fr) 2008-06-12
WO2008070268A2 (fr) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2008070268A3 (fr) Compositions pharmaceutiques
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2012061290A3 (fr) Compositions pesticides et procédés associés
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2009152356A3 (fr) Composés et compositions utiles pour le traitement de la malaria
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2007093627A3 (fr) Composition biocide
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2010132882A8 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2010049454A3 (fr) Composition antimicrobienne tirée de copépodes
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2010014258A3 (fr) Conjugués possédant une liaison libérable
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2007144057A3 (fr) Carbone antimicrobien
WO2012075015A3 (fr) Compositions pharmaceutiques orales de métronidazole
WO2010062506A3 (fr) Inhibiteurs de cyp17 décahydro-1h-indénoquinolinone et décahydro-3h-cyclopentaphénanthridinone
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871139

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007871139

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009531645

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2665841

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12444521

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载